α2δ ligand: A new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Gut

Volumn 56, Issue 10, 2007, Pages 1337-1338

  Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ASIMADOLINE; CLONIDINE; FEDOTOZINE; FENTANYL; GABAPENTIN; OCTREOTIDE; PREGABALIN; TALNETANT; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE; LIGAND;

ALLODYNIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DIZZINESS; DRUG BINDING AND TRANSPORT; DRUG EFFICACY; DRUG MEGADOSE; DRUG UPTAKE; HUMAN; HYPERSENSITIVITY; IRRITABLE COLON; LOW DRUG DOSE; NONHUMAN; NOTE; PRIORITY JOURNAL; SOMNOLENCE; VISCERAL PAIN; DRUG EFFECT; HYPERALGESIA; PAIN THRESHOLD; PATHOPHYSIOLOGY; RECTUM;

ANALGESICS; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPERALGESIA; IRRITABLE BOWEL SYNDROME; LIGANDS; PAIN THRESHOLD; RECTUM;

EID: 34948910570     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.127514     Document Type: Note

References (21)

1. Wolf M, Eberhart A, Glossmann H, et al. Visualization of the domain structure of an L-type Ca2+ channel using electron cryo-microscopy. J Mol Biol 2003;332:171-82.
2. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia, 2004;45(Suppl 6), 13-8.
3. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029-37.
4. Field MJ, Cox PJ, Stott E, et al. Identification of the α2δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006;103:17537-42.
5. Field MJ, McCleary S, Hughes J, et al. Gabapentin and pregabalin, but not morphine and amitriptyline, black both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999;80:391-8.
6. Han DW, Kweon TD, Lee JS, et al. Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. Yonsei Med J 2007;48:41-7.
7. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133- 44.
8. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82.
9. Diop L, Raymond F, Fargeau H, et al. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002;302:1013-22.
10. Eutamene H, Coelho AM, Theodorou V, et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther 2000;295:162-7.
11. Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation α2δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56:1218-25.
12. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-55.
13. Simren M, Simms L, D'Souza D, et al. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. Aliment Pharmacol Ther 2003;17:279-87.
14. Delvaux M, Louvel D, Lagier E, et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999;116:38-45.
15. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46.
16. Bradette M, Delvaux M, Staumont G, et al. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171-8.
17. Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993;265:G742-51.
18. Schwetz I, Naliboff B, Munakata J, et al. Antihyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:123-31.
19. Houghton LA, Cremonini F, Camilleri M, et al. Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil, published online first 1 May 2007.
20. Lembo T, Naliboff BD, Matin K, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000;87:137-47.
21. Viramontes BE, Malcolm A, Camilleri M, et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G1468-76.